Impact Factor
3.43
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.83
858 total citations
h5-index
35
h5 depth signal
Cited share
68.4%
212 of 310
Total citations
858
Citation footprint
Metric signal
2.29
External metric anchor
Self-citation
8.3%
71 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
898
Canada
71
China
15
Australia
13
Brazil
8
Citing Fields of Research
Substance Abuse
1,366
Anesthetic & Pain Medicine
429
Psychiatry
68
Nicotine Addiction Treatment
67
Psychiatry & Psychology
45
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,126
Articles tracked across the journal lifetime
Indexed publication set
310
212 cited publications
Last 12 months
192
16.0 publications/month
Open access share
16.1%
31 OA publications in the last year
Leading citing country
United States
898 citing publications
Leading citing field
Substance Abuse
1,366 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v5n1, Mar. 2011-
v5n1, Mar. 2011-
Research Focus & Classification
Indexed Subjects
Substance Abuse
Issuing & Sponsoring Bodies
Contributor
American Society of Addiction Medicine
Broad Categories
Substance-Related Disorders
Substance Abuse
MeSH Descriptors
Substance-Related Disorders.
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/adm.0000000000001785
Open DOI
Kratom-labeled Products in the US Compared With Traditionally Consumed Natural Kratom in Southeast Asia
Kratom-labeled products consumed in the United States and natural kratom consumed in Southeast Asia (SEA) are very different in their chemistry and safety profiles. Water-based decoction, frequently consumed in SEA, is prepared using fre...
02
DOI 10.1097/adm.0000000000001789
Open DOI
Managing the Hospital Capacity Challenges of Medetomidine Withdrawal: A Retrospective Report of Dexmedetomidine Use in Intermediate Care Units
Objectives: Medetomidine, a veterinary alpha-2-adrenergic agonist, has emerged as a dominant adulterant in the Philadelphia illicit opioid supply, producing a severe withdrawal syndrome requiring significant inpatient support. We develop...
03
DOI 10.1097/adm.0000000000001788
Open DOI
Ketamine Use Disorder and Entrenchment of Delusional Beliefs: A Case Report
Background: Ketamine has gained increasing attention for its therapeutic potential, yet concerns remain regarding its misuse and the associated complications of its use. Ketamine use and ketamine use disorder can induce psychotic symptom...
04
DOI 10.1097/adm.0000000000001777
Open DOI
Liver Transplantation Outcomes in Patients With and Without Alcohol Use Disorder Diagnosis: Evidence From a Nationwide Cohort Study
Objectives: Alcohol-related liver disease is the primary indication for liver transplantation, yet posttransplant outcomes among recipients with an alcohol use disorder (AUD) diagnosis remain inconsistent. This study assesses whether AUD...
05
DOI 10.1097/adm.0000000000001784
Open DOI
Visiting Nurse Services-facilitated Outpatient Low-dose Buprenorphine Initiation and Engagement in Severe Mental Illness and Ongoing Fentanyl Use: A Case Report
Background and Objectives: Outpatient low-dose buprenorphine initiation (LDBI) is challenging for individuals with severe mental illness and poor treatment adherence. Visiting nurse services (VNS) may support LDBI in these complex patien...
06
DOI 10.1097/adm.0000000000001780
Open DOI
Scoping Review of Implementation Science in Digital Intervention Research for Substance Use Disorders
Objectives: Digital substance use interventions (DSUI) have demonstrated effectiveness in preventing, treating, and supporting recovery of substance use disorders (SUD), but their large-scale adoption and sustained implementation remain ...
07
DOI 10.1097/adm.0000000000001786
Open DOI
Clinical Outcomes of a 3-day Benzodiazepine Detoxification Protocol With Continuous Subcutaneous Flumazenil Infusion: An Open-label Pilot Study
Objectives: Abstinence rates of benzodiazepine tapering in individuals with sedative, hypnotic, or anxiolytic use disorder (SHA‑UD) are approximately 50%. Continuous subcutaneous flumazenil infusion during tapering may increase success r...
08
DOI 10.1097/adm.0000000000001782
Open DOI
When Buprenorphine Was Not Enough: Methadone Treatment of Tianeptine Use Disorder
Introduction: Tianeptine, approved in 25 countries for depression treatment, is an atypical tricyclic with clinically relevant µ-opioid receptor agonist activity at high doses. Tianeptine is not approved by the Food and Drug Administrati...
09
DOI 10.1097/adm.0000000000001760
Open DOI
Insights About Nitazene Use From Self-reported Experiences on Reddit Obtained Using Natural Language Processing
Introduction: Nitazenes are an emerging class of highly potent synthetic opioids not approved for clinical use. Knowledge of nitazene-associated practices and clinical effects remains limited. Reddit contains nitazene-related discussions...
10
DOI 10.1097/adm.0000000000001776
Open DOI
In-Hospital Substance Use: A Qualitative Study of Patient and Staff Experiences
Objectives: To understand patient and staff experiences with in-hospital substance use (IHSU) and develop recommendations to better support patients and staff navigating IHSU. Methods: Semi-structured qualitative interviews with patients...
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Also issued online.